Hengrui Medicine has recently announced the acceptance of its application for marketing authorization of Haitrepavir Ethylamine Tablets by the National Medical Products Administration. This drug is specifically designed for the treatment of persistent and chronic primary immune thrombocytopenia (ITP) in adult and pediatric patients aged 6 and above who have shown an inadequate response to prior therapies, such as glucocorticoids and immunoglobulin. Haitrepavir Ethylamine Tablets, an orally administered, non-peptide thrombopoietin receptor agonist independently developed by Hengrui Medicine, functions by activating relevant signaling pathways to stimulate platelet production.

Furthermore, the National Healthcare Security Administration has recently issued a preliminary review announcement regarding adjustments to the drug directories for basic medical insurance, maternity insurance, and work-related injury insurance, as well as the directory of commercial insurance innovative drugs. Notably, several companies, including Hengrui Medicine, have been included in these lists. Additionally, CICC has recommended investors to keep a close eye on stocks like Hengrui Medicine.